Tumor vaccine

Cancer is an increasing threat with a great demand for novel, improved therapies. Vaccines can help the patient to build up own protective immunity. 

In a joint project, MediGene, Martinsried, Germany, and Biomed developed a new generation of anti-cancer vaccines targeted against the HER-2 molecule. Her-2 is expressed in breast cancer, but also on many other tumor entities such as ovarian and gastric cancer.

The new vaccine is based on HER-2 mimotopes displayed by Adeno-associated virus-like particles (AAVLPs) and has proven effective in preclinical models.

AAVLP 1

 

 

 

Figure: This AAVLP particle (blue) shows a dense display of HER-2 mimotope peptides on its surface (red). 


Published Biomed Patent

WO2013037961 (A1) - 2013-03-21. Anti-Her2 vaccine based upon AAV derived multimeric structures.

Inventors: Michaelis Uwe, Jensen-Jarolim Erika, Rehfuss Christoph, Weghofer Margit.

Scientific publications

Construction and evaluation of a novel AAV-displayed HER-2 mimotope anti-cancer vaccine. Singer J, Manzano-Szalai K, Fazekas J, Lukschal A, Thell K, Stremnitzer C, Roth-Walter F, Weghofer M, Ritter M, Hörer M, Lux K, Michaelis U, Jensen-Jarolim E. Oncoimmunology, 2016, in press.

Cancer vaccines inducing antibody production: more pros than cons.Jensen-Jarolim E, Singer J. Expert Rev Vaccines. 2011 Sep;10(9):1281-9. doi: 10.1586/erv.11.105. Review.

Mimotope vaccination-from allergy to cancer. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Expert Opin Biol Ther. 2009 Apr;9(4):493-506. doi: 10.1517/14712590902870386 . Review.

Vaccination strategies based on the mimotope concept. Szalai K, Jensen-Jarolim E, Pali-Schöll I. G Ital Dermatol Venereol. 2008 Apr;143(2):95-104. Review.

Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Brämswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Clin Cancer Res. 2007 Nov 1;13(21):6501-8.

Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Riemer AB, Jensen-Jarolim E. Immunol Lett. 2007 Oct 31;113(1):1-5. Epub 2007 Aug 22. Review.

Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Cancer Res. 2007 Apr 1;67(7):3406-11.

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Förster-Wald E, Jensen-Jarolim E, Lode HN. Cancer Res. 2006 Nov 1;66(21):10567-75.

Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Riemer AB, Förster-Waldl E, Brämswig KH, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E. Eur J Immunol. 2006 May;36(5):1267-74.

Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.

Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition.Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Mol Immunol. 2005 May;42(9):1121-4. Epub 2005 Jan 8.

High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E. Cancer Immunol Immunother. 2005 Jul;54(7):677-84. Epub 2004 Nov 24.

Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E. J Immunol. 2004 Jul 1;173(1):394-401.